Literature DB >> 25481549

How undifferentiated arthritis evolves into chronic arthritis.

D van der Woude1, R E M Toes2, H U Scherer3.   

Abstract

Undifferentiated arthritis (UA) is a frequently occurring clinical presentation with a variable outcome. While some forms of UA will spontaneously remit, other forms will progress to chronic arthritis; an outcome that would preferably be prevented. Which immunological factors are normally at the basis of resolution of inflammation, and what, on the other hand, causes inflammation to persist? This review provides an overview of the immunological mechanisms involved in these two scenarios, including specific examples of how these mechanisms apply, or can be influenced in rheumatic diseases. Furthermore, what do we know about risk factors for chronic arthritis, such as the development of autoantibodies? The recent years have provided many insights concerning risk factors for autoantibody-positive versus autoantibody-negative rheumatoid arthritis, which are discussed along with a possible pathophysiological model incorporating autoantibodies into the larger process of disease development. Finally, the evolution of the autoantibody response over time is described.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoantibodies; Disease course; Inflammation; Rheumatoid arthritis; Risk factors

Mesh:

Substances:

Year:  2014        PMID: 25481549     DOI: 10.1016/j.berh.2014.10.013

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  2 in total

1.  VEGF Profile in Early Undifferentiated Arthritis Cohort.

Authors:  Regina Sakalyte; Loreta Bagdonaite; Sigita Stropuviene; Sarune Naktinyte; Algirdas Venalis
Journal:  Medicina (Kaunas)       Date:  2022-06-20       Impact factor: 2.948

2.  Autoantibodies, C-reactive protein, erythrocyte sedimentation rate and serum cytokine profiling in monitoring of early treatment.

Authors:  Edyta Brzustewicz; Izabella Henc; Agnieszka Daca; Maria Szarecka; Malgorzata Sochocka-Bykowska; Jacek Witkowski; Ewa Bryl
Journal:  Cent Eur J Immunol       Date:  2017-10-30       Impact factor: 2.085

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.